Welcome to LookChem.com Sign In|Join Free

CAS

  • or
methyl (1R,2R,4S)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-4-{[2,3,6-trideoxy-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy}-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

11002-83-8

Post Buying Request

11002-83-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • methyl (1R,2R,4S)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-4-{[2,3,6-trideoxy-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy}-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate

    Cas No: 11002-83-8

  • Need to discuss

  • No requirement

  • Adequate

  • Golden Pharma Co., Limited
  • Contact Supplier
  • methyl (1R,2R,4S)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-4-{[2,3,6-trideoxy-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy}-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate

    Cas No: 11002-83-8

  • Need to discuss

  • No requirement

  • Adequate

  • GL Biochem (Shanghai) Ltd.
  • Contact Supplier

11002-83-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 11002-83-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,1,0,0 and 2 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 11002-83:
(7*1)+(6*1)+(5*0)+(4*0)+(3*2)+(2*8)+(1*3)=38
38 % 10 = 8
So 11002-83-8 is a valid CAS Registry Number.

11002-83-8Downstream Products

11002-83-8Relevant articles and documents

Characterization of rhodosaminyl transfer by the AknS/AknT glycosylation complex and its use in reconstituting the biosynthetic pathway of aclacinomycin A

Leimkuhler, Catherine,Fridman, Micha,Lupoli, Tania,Walker, Suzanne,Walsh, Christopher T.,Kahne, Daniel

, p. 10546 - 10550 (2007)

The tetracyclic core of anthracycline natural products with antitumor activity such as aclacinomycin A are tailored during biosynthesis by regioselective glycosylation. We report the first synthesis of TDP-L-rhodosamine and demonstrate that the glycosyltransferase AknS transfers L-rhodosamine to the aglycone to initiate construction of the side-chain trisaccharide. The partner protein AknT accelerates AknS turnover rate for L-rhodosamine transfer by 200-fold. AknT does not affect the Km but rather affects the kcat. Using these data, we propose that AknT causes a conformational change in AknS that stabilizes the transition state and ultimately enhances transfer. When the subsequent glycosyltransferase AknK and its substrate TDP-L-fucose are also added to the aglycone, the disaccharide and low levels of a fully reconstituted trisaccharide form of aclacinomycin are observed.

Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents

Wander, Dennis P. A.,Van Der Zanden, Sabina Y.,Van Der Marel, Gijsbert A.,Overkleeft, Herman S.,Neefjes, Jacques,Codée, Jeroen D. C.

, p. 12814 - 12829 (2020/11/17)

Anthracycline anticancer drugs doxorubicin and aclarubicin have been used in the clinic for several decades to treat various cancers. Although closely related structures, their molecular mode of action diverges, which is reflected in their biological activity profile. For a better understanding of the structure-function relationship of these drugs, we synthesized ten doxorubicin/aclarubicin hybrids varying in three distinct features: Aglycon, glycan, and amine substitution pattern. We continued to evaluate their capacity to induce DNA breaks, histone eviction, and relocated topoisomerase IIα in living cells. Furthermore, we assessed their cytotoxicity in various human tumor cell lines. Our findings underscore that histone eviction alone, rather than DNA breaks, contributes strongly to the overall cytotoxicity of anthracyclines, and structures containing N,N-dimethylamine at the reducing sugar prove that are more cytotoxic than their nonmethylated counterparts. This structural information will support further development of novel anthracycline variants with improved anticancer activity.

Antitumor anthracycline antibiotics, aclacinomycin A and analogues. II. Structural determination

Oki,Kitamura,Matsuzawa,Shibamoto,Ogasawara,Yoshimoto,Inui,Naganawa,Takeuchi,Umezawa

, p. 801 - 819 (2007/10/10)

The structures of aclacinomycins A and B and 19 analogues were determined by a combination of chemical conversions and degradations and spectral interpretations.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 11002-83-8